What is Erasca Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Erasca's interest expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Erasca's Operating Income for the
three
months ended in Mar. 2024 was $ -38.85 Mil. Erasca's Interest Expense for the
three
months ended in Mar. 2024 was $ 0.00 Mil.
GuruFocus does not calculate Erasca's interest coverage with the available data.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Erasca Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Erasca (NAS:ERAS) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Erasca's Interest Expense for the
three
months ended in Mar. 2024 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-38.85 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $50.81 Mil.
Erasca's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| GuruFocus does not calculate Erasca's interest coverage with the available data. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Ben Graham prefers companies' interest coverage to be at least 5. Erasca Inc has enough cash to cover all of its debt. Its financial situation is stable.
Erasca (Erasca) Business Description
Traded in Other Exchanges
N/A
Address
3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Executives
| Jonathan E Lim |
director, 10 percent owner, officer: See Remarks |
11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121 |
| Start Valerie Denise Harding |
director |
C/O IGNYTA, INC., 11111 FLINTKOTE AVE., SAN DIEGO CA 92121 |
| Alexander W. Casdin |
director |
C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121 |
| Shannon Morris |
officer: Chief Medical Officer |
C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO CA 92121 |
| James Arthur Bristol |
director |
C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
| Cormorant Asset Management, Lp |
director |
200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
| Bihua Chen |
director |
C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
| Cormorant Global Healthcare Master Fund, Lp |
director |
200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
| Cormorant Private Healthcare Fund Ii, Lp |
director |
200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
| Jean I Liu |
director |
21823 30TH DRIVE SE, BOTHELL WA 98021 |
| Pratik S Multani |
director |
C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
| Julie Hambleton |
director |
C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
| Ebun Garner |
officer: General Counsel |
C/O ALPHATEC HOLDINGS, INC., 2051 PALOMAR AIRPORT ROAD, CARLSBAD CA 92011 |
| Lim Conyee T. |
10 percent owner |
C/O ERASCA, INC., 10835 ROAD TO THE CURE #140, SAN DIEGO CA 92121 |
| Arch Venture Fund X, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Erasca (Erasca) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ERAS has been successfully added to your 